A First-in-Human Study of Repeat Dosing with REGN2810, A Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies - Regional Cancer Care Associates LLC

Clinical Trials

A First-in-Human Study of Repeat Dosing with REGN2810, A Monoclonal, Fully Human Antibody to Programmed Death – 1 (PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies

Type of Cancer

Warning: implode(): Invalid arguments passed in /home/region33/public_html/wp-content/themes/regionalcancercenter/single-clinical-trials.php on line 42
Locations
Sponsor
Regeneron
Protocol Number
Regeneron R2810-ONC-1423
Cancer Diagnosis
To Learn More Call
201-510-0910